Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics

Christopher A Ross, Ira Shoulson

Research output: Contribution to journalArticle

Abstract

Huntington disease (HD) is characterized by motor, cognitive and behavioral abnormalities that typically emerge in adulthood in persons who have inherited the mutant gene. HD has a single genetic cause, a well-defined neuropathology, and informative pre-manifest predictive genetic testing. Thus, it has been possible to develop imaging biomarkers of HD progression, not just in the period of manifest illness, but also in the prodromal or "premanifest" period. Striatal atrophy is the most studied, and shows steady progression beginning in the prodromal period beginning up to 15 years before predicted onset, and continuing through the period of manifest illness. Therapeutic targets for HD include the huntingtin protein itself, either by reducing its levels with antisense oligonucleotides or siRNA, or potentially by intervening via posttranslational modifications such as phosphorylation, acetylation, SUMOylation, or proteolytic cleavage. Other strategies involve bolstering the cell's ability to deal with abnormal proteins, either via chaperones or protein degradation machinery. It may be possible to counteract the abnormal transcription caused by mutant huntingtin, with histone deacetylase inhibitors, or to enhance relevant gene products such as Brain Derived Neurotrophic Factor (BDNF). Another tactic is to enhance cellular metabolic defenses, such as with creatine or Coenzyme Q10. Strategies are being devised to use biomarkers, and administer therapeutic agents which can be given safely for long periods of time during the proodromal period, with a goal not just to slow progression, but to delay, or conceivably even prevent, the onset of clinical HD.

Original languageEnglish (US)
JournalParkinsonism and Related Disorders
Volume15
Issue numberSUPPL. 3
DOIs
StatePublished - Dec 2009

Fingerprint

Huntington Disease
Biomarkers
coenzyme Q10
Sumoylation
Prodromal Symptoms
Therapeutics
Corpus Striatum
Histone Deacetylase Inhibitors
Aptitude
Creatine
Antisense Oligonucleotides
Brain-Derived Neurotrophic Factor
Genetic Testing
Post Translational Protein Processing
Acetylation
Small Interfering RNA
Proteolysis
Genes
Atrophy
Disease Progression

Keywords

  • BDNF
  • Coenzyme Q10
  • HDAC
  • huntingtin
  • MRI
  • PHAROS
  • PREDICT-HD
  • Rhes
  • striatum
  • TRACK-HD

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology

Cite this

Huntington disease : pathogenesis, biomarkers, and approaches to experimental therapeutics. / Ross, Christopher A; Shoulson, Ira.

In: Parkinsonism and Related Disorders, Vol. 15, No. SUPPL. 3, 12.2009.

Research output: Contribution to journalArticle

@article{53e2f61dc1e547099129efc18fcadf30,
title = "Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics",
abstract = "Huntington disease (HD) is characterized by motor, cognitive and behavioral abnormalities that typically emerge in adulthood in persons who have inherited the mutant gene. HD has a single genetic cause, a well-defined neuropathology, and informative pre-manifest predictive genetic testing. Thus, it has been possible to develop imaging biomarkers of HD progression, not just in the period of manifest illness, but also in the prodromal or {"}premanifest{"} period. Striatal atrophy is the most studied, and shows steady progression beginning in the prodromal period beginning up to 15 years before predicted onset, and continuing through the period of manifest illness. Therapeutic targets for HD include the huntingtin protein itself, either by reducing its levels with antisense oligonucleotides or siRNA, or potentially by intervening via posttranslational modifications such as phosphorylation, acetylation, SUMOylation, or proteolytic cleavage. Other strategies involve bolstering the cell's ability to deal with abnormal proteins, either via chaperones or protein degradation machinery. It may be possible to counteract the abnormal transcription caused by mutant huntingtin, with histone deacetylase inhibitors, or to enhance relevant gene products such as Brain Derived Neurotrophic Factor (BDNF). Another tactic is to enhance cellular metabolic defenses, such as with creatine or Coenzyme Q10. Strategies are being devised to use biomarkers, and administer therapeutic agents which can be given safely for long periods of time during the proodromal period, with a goal not just to slow progression, but to delay, or conceivably even prevent, the onset of clinical HD.",
keywords = "BDNF, Coenzyme Q10, HDAC, huntingtin, MRI, PHAROS, PREDICT-HD, Rhes, striatum, TRACK-HD",
author = "Ross, {Christopher A} and Ira Shoulson",
year = "2009",
month = "12",
doi = "10.1016/S1353-8020(09)70800-4",
language = "English (US)",
volume = "15",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Huntington disease

T2 - pathogenesis, biomarkers, and approaches to experimental therapeutics

AU - Ross, Christopher A

AU - Shoulson, Ira

PY - 2009/12

Y1 - 2009/12

N2 - Huntington disease (HD) is characterized by motor, cognitive and behavioral abnormalities that typically emerge in adulthood in persons who have inherited the mutant gene. HD has a single genetic cause, a well-defined neuropathology, and informative pre-manifest predictive genetic testing. Thus, it has been possible to develop imaging biomarkers of HD progression, not just in the period of manifest illness, but also in the prodromal or "premanifest" period. Striatal atrophy is the most studied, and shows steady progression beginning in the prodromal period beginning up to 15 years before predicted onset, and continuing through the period of manifest illness. Therapeutic targets for HD include the huntingtin protein itself, either by reducing its levels with antisense oligonucleotides or siRNA, or potentially by intervening via posttranslational modifications such as phosphorylation, acetylation, SUMOylation, or proteolytic cleavage. Other strategies involve bolstering the cell's ability to deal with abnormal proteins, either via chaperones or protein degradation machinery. It may be possible to counteract the abnormal transcription caused by mutant huntingtin, with histone deacetylase inhibitors, or to enhance relevant gene products such as Brain Derived Neurotrophic Factor (BDNF). Another tactic is to enhance cellular metabolic defenses, such as with creatine or Coenzyme Q10. Strategies are being devised to use biomarkers, and administer therapeutic agents which can be given safely for long periods of time during the proodromal period, with a goal not just to slow progression, but to delay, or conceivably even prevent, the onset of clinical HD.

AB - Huntington disease (HD) is characterized by motor, cognitive and behavioral abnormalities that typically emerge in adulthood in persons who have inherited the mutant gene. HD has a single genetic cause, a well-defined neuropathology, and informative pre-manifest predictive genetic testing. Thus, it has been possible to develop imaging biomarkers of HD progression, not just in the period of manifest illness, but also in the prodromal or "premanifest" period. Striatal atrophy is the most studied, and shows steady progression beginning in the prodromal period beginning up to 15 years before predicted onset, and continuing through the period of manifest illness. Therapeutic targets for HD include the huntingtin protein itself, either by reducing its levels with antisense oligonucleotides or siRNA, or potentially by intervening via posttranslational modifications such as phosphorylation, acetylation, SUMOylation, or proteolytic cleavage. Other strategies involve bolstering the cell's ability to deal with abnormal proteins, either via chaperones or protein degradation machinery. It may be possible to counteract the abnormal transcription caused by mutant huntingtin, with histone deacetylase inhibitors, or to enhance relevant gene products such as Brain Derived Neurotrophic Factor (BDNF). Another tactic is to enhance cellular metabolic defenses, such as with creatine or Coenzyme Q10. Strategies are being devised to use biomarkers, and administer therapeutic agents which can be given safely for long periods of time during the proodromal period, with a goal not just to slow progression, but to delay, or conceivably even prevent, the onset of clinical HD.

KW - BDNF

KW - Coenzyme Q10

KW - HDAC

KW - huntingtin

KW - MRI

KW - PHAROS

KW - PREDICT-HD

KW - Rhes

KW - striatum

KW - TRACK-HD

UR - http://www.scopus.com/inward/record.url?scp=72149084425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72149084425&partnerID=8YFLogxK

U2 - 10.1016/S1353-8020(09)70800-4

DO - 10.1016/S1353-8020(09)70800-4

M3 - Article

C2 - 20082975

AN - SCOPUS:72149084425

VL - 15

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - SUPPL. 3

ER -